Switch theme
Sign up to access all valuation multiples
SC Ropharma SA is engaged in the production, distribution, and Retail sale of pharmaceutical products in specialized stores. Its product portfolio comprises over 50 products in the form of tablets, powders, capsules, and syrups covering 21 therapeutic areas.
1952
1.3K+
LTM Revenue n/a
LTM EBITDA n/a
$46.8M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
SC Ropharma has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, SC Ropharma achieved revenue of $224M and an EBITDA of $10.2M.
SC Ropharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See SC Ropharma valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $203M | $224M | XXX | XXX | XXX |
| Gross Profit | $21.2M | $29.2M | XXX | XXX | XXX |
| Gross Margin | 10% | 13% | XXX | XXX | XXX |
| EBITDA | $8.3M | $10.2M | XXX | XXX | XXX |
| EBITDA Margin | 4% | 5% | XXX | XXX | XXX |
| Net Profit | $2.4M | $2.0M | XXX | XXX | XXX |
| Net Margin | 1% | 1% | XXX | XXX | XXX |
| Net Debt | $14.3M | $13.7M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 21, 2025, SC Ropharma's stock price is RON 0 (or $0).
SC Ropharma has current market cap of RON 77.2M (or $17.1M), and EV of RON 211M (or $46.8M).
See SC Ropharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $46.8M | $17.1M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 21, 2025, SC Ropharma has market cap of $17.1M and EV of $46.8M.
SC Ropharma's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate SC Ropharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for SC Ropharma and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $46.8M | XXX | XXX | XXX |
| EV/Revenue | 0.2x | XXX | XXX | XXX |
| EV/EBITDA | 4.6x | XXX | XXX | XXX |
| P/E | 10.0x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 8.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSC Ropharma's NTM/LTM revenue growth is n/a
SC Ropharma's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged n/a for the same period.
Over next 12 months, SC Ropharma's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate SC Ropharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for SC Ropharma and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 10% | XXX | XXX | XXX | XXX |
| EBITDA Margin | N/A | XXX | XXX | XXX | XXX |
| EBITDA Growth | 22% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | N/A | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.2M | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 0% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| MedPlus India | XXX | XXX | XXX | XXX | XXX | XXX |
| Pague Menos | XXX | XXX | XXX | XXX | XXX | XXX |
| Droga Raia | XXX | XXX | XXX | XXX | XXX | XXX |
| Redcare Pharmacy | XXX | XXX | XXX | XXX | XXX | XXX |
| Oriola | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
SC Ropharma acquired XXX companies to date.
Last acquisition by SC Ropharma was XXXXXXXX, XXXXX XXXXX XXXXXX . SC Ropharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was SC Ropharma founded? | SC Ropharma was founded in 1952. |
| Where is SC Ropharma headquartered? | SC Ropharma is headquartered in Romania. |
| How many employees does SC Ropharma have? | As of today, SC Ropharma has 1.3K+ employees. |
| Is SC Ropharma publicy listed? | Yes, SC Ropharma is a public company listed on BSE. |
| What is the stock symbol of SC Ropharma? | SC Ropharma trades under RPH ticker. |
| When did SC Ropharma go public? | SC Ropharma went public in 1997. |
| Who are competitors of SC Ropharma? | Similar companies to SC Ropharma include e.g. MedPlus India, Pague Menos, Droga Raia, Redcare Pharmacy. |
| What is the current market cap of SC Ropharma? | SC Ropharma's current market cap is $17.1M |
| What is the current revenue growth of SC Ropharma? | SC Ropharma revenue growth between 2023 and 2024 was 10%. |
| Is SC Ropharma profitable? | Yes, SC Ropharma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
